Current risks for blood borne viral illness in blood transfusions.

Y. Podnos,R. Williams

Western Journal of Medicine

Abstract:placed intraluminally, the potential for graft dilatation may be limited by the surrounding aortic wall, but its natural history is yet to be defined. Nevertheless, transluminally placed endovascular grafts present a less invasive approach to treatment of aneurysms and therefore have tremendous intrinsic appeal. There is need for well controlled clinical trials in which the various transluminally placed endovascular graft devices are compared with standard operative treatment methods in groups of patients with aortic aneurysm morphology and similar risk factors. In particular, these studies will need to document the effective long-term treatment of patients with aneurysms having acceptable early and late patency and morbidity and mortality rates. With cautious optimism, it is conceivable that these endovascular devices may replace anywhere between 30% to 70% of current vascular prosthetic grafts, depending on how effective and safe they prove to be.